Advertisement

Cancer Causes & Control

, Volume 29, Issue 7, pp 657–665 | Cite as

Black/white differences in treatment and survival among women with stage IIIB–IV breast cancer at diagnosis: a US population-based study

  • Lindsey Enewold
  • Dolly C. Penn
  • Jennifer L. Stevens
  • Linda C. Harlan
Original paper
  • 114 Downloads

Abstract

Introduction

Non-Hispanic black (NHB) women with breast cancer have poorer survival than non-Hispanic white (NHW) women. Although NHB women are more often diagnosed at later stages, it is less established whether racial disparities exist among women diagnosed with late-stage breast cancer, particularly when care is provided in the community setting.

Methods

Treatment and survival were examined by race/ethnicity among women diagnosed in 2012 with stage IIIB–IV breast cancer using the National Cancer Institute’s population-based Patterns of Care Study. Medical records were re-abstracted and treating physicians were contacted to verify therapy. Vital status was available through 2014.

Results

A total of 533 women with stage IIIB–C and 625 with stage IV tumors were included; NHW women comprised about 70% of each group. Among women with stage IIIB–C disease, racial/ethnicity variations in systemic treatment were not observed but there was a borderline association indicating worse all-cause mortality among NHB women (hazard ratio 1.52; 95% confidence interval (CI) 0.96–2.41). In contrast, among women with stage IV disease, borderline associations indicating NHB women were more likely to receive chemotherapy (OR 1.44, 95% CI 0.90–2.30) and, among those with hormone receptor-positive tumors, less likely to receive endocrine therapy (OR 0.60, 95% CI 0.35–1.04). All-cause mortality did not vary by race/ethnicity for stage IV disease (hazard ratio 0.92; 95% CI 0.68–1.25).

Conclusions

More research is needed to identify additional factors associated with the potential survival disparities among women with stage IIIB–C disease and potential treatment disparities among women with stage IV disease.

Keywords

Breast cancer Disparity Chemotherapy Endocrine therapy Survival HER2 

Notes

Acknowledgments

This study was made possible through the efforts of the Principal Investigators and the personnel at the Surveillance, Epidemiology, and End Results registries.

Funding

National Cancer Institute contracts: HHSN261201000024C; HHSN261201000025C, HHSN261201000032C, HHSN261201000027C, HHSN261201000026C, HHSN261201000140C, HHSN261201000037C, HHSN261201000033C, HHSN261201000034C, HHSN261201000035C, HHSN261201000029C, HHSN261201000031C, HHSN261201000028C, and HHSN261201000030C.

Compliance with ethical standards

Conflict of interest

The authors have disclosed that they have no financial interests, arrangements, affiliations, or commercial interests with the manufacturers of any products discussed in this article or their competitors.

Supplementary material

10552_2018_1045_MOESM1_ESM.doc (299 kb)
Supplementary material 1 (DOC 299 KB)

References

  1. 1.
    Howlader N NA, Krapcho M, Miller D, Bishop K, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds) SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. Accessed 21 March 2017
  2. 2.
    Chan DS, Vieira AR, Aune D, Bandera EV, Greenwood DC, McTiernan A, Navarro Rosenblatt D, Thune I, Vieira R, Norat T (2014) Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol 25(10):1901–1914.  https://doi.org/10.1093/annonc/mdu042 CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Khanfir A, Lahiani F, Bouzguenda R, Ayedi I, Daoud J, Frikha M (2013) Prognostic factors and survival in metastatic breast cancer: a single institution experience. Rep Pract Oncol Radiother 18(3):127–132.  https://doi.org/10.1016/j.rpor.2013.01.001 CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Parise CA, Caggiano V (2013) Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000–2010. BMC Cancer 13:449.  https://doi.org/10.1186/1471-2407-13-449 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Walker GV, Grant SR, Guadagnolo BA, Hoffman KE, Smith BD, Koshy M, Allen PK, Mahmood U (2014) Disparities in stage at diagnosis, treatment, and survival in nonelderly adult patients with cancer according to insurance status. J Clin Oncol 32(28):3118–3125.  https://doi.org/10.1200/jco.2014.55.6258 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Bear HD, Tang G, Rastogi P, Geyer CE Jr, Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SM, Mamounas EP, Wolmark N (2015) Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol.  https://doi.org/10.1016/s1470-2045(15)00041-8 PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Daw J (2017) Contribution of four comorbid conditions to racial/ethnic disparities in mortality risk. Am J Prev Med 52(1S1):S95–S102CrossRefPubMedGoogle Scholar
  8. 8.
    Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL (2016) Trends in obesity among adults in the United States, 2005 to 2014. JAMA 315(21):2284–2291.  https://doi.org/10.1001/jama.2016.6458 CrossRefPubMedGoogle Scholar
  9. 9.
    Akinyemiju T, Moore JX, Ojesina AI, Waterbor JW, Altekruse SF (2016) Racial disparities in individual breast cancer outcomes by hormone-receptor subtype, area-level socio-economic status and healthcare resources. Breast Cancer Res Treat 157(3):575–586.  https://doi.org/10.1007/s10549-016-3840-x CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Hines RB, Markossian TW (2012) Differences in late-stage diagnosis, treatment, and colorectal cancer-related death between rural and urban African Americans and whites in Georgia. J Rural Health 28(3):296–305.  https://doi.org/10.1111/j.1748-0361.2011.00390.x CrossRefPubMedGoogle Scholar
  11. 11.
    Markossian TW, Hines RB, Bayakly R (2014) Geographic and racial disparities in breast cancer-related outcomes in Georgia. Health Serv Res 49(2):481–501.  https://doi.org/10.1111/1475-6773.12096 CrossRefPubMedGoogle Scholar
  12. 12.
    Sheppard VB, Oppong BA, Hampton R, Snead F, Horton S, Hirpa F, Brathwaite EJ, Makambi K, Onyewu S, Boisvert M, Willey S (2015) Disparities in breast cancer surgery delay: the lingering effect of race. Ann Surg Oncol 22(9):2902–2911.  https://doi.org/10.1245/s10434-015-4397-3 CrossRefPubMedGoogle Scholar
  13. 13.
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v2.2017Google Scholar
  14. 14.
    Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M (2015) Surgery of the primary tumor in de novo metastatic breast cancer: to do or not to do? Eur J Surg Oncol 41(10):1288–1292.  https://doi.org/10.1016/j.ejso.2015.07.013 CrossRefPubMedGoogle Scholar
  15. 15.
    Khan SA (2016) Surgical management of de novo stage IV breast cancer. Semin Radiat Oncol 26(1):79–86.  https://doi.org/10.1016/j.semradonc.2015.08.004 CrossRefPubMedGoogle Scholar
  16. 16.
    Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703–711CrossRefPubMedGoogle Scholar
  17. 17.
    Yu M, Tatalovich Z, Gibson JT, Cronin KA (2014) Using a composite index of socioeconomic status to investigate health disparities while protecting the confidentiality of cancer registry data. Cancer Causes Control 25:81–92CrossRefPubMedGoogle Scholar
  18. 18.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMedGoogle Scholar
  19. 19.
    National Cancer Institute. Surveillance, epidemiology, and end results program. Algorithm for derived HER2 summary variable. https://seer.cancer.gov/seerstat/databases/ssf/her2-derived.html. Accessed 19 Sept 2017
  20. 20.
    Griggs JJ, Hawley ST, Graff JJ, Hamilton AS, Jagsi R, Janz NK, Mujahid MS, Friese CR, Salem B, Abrahamse PH, Katz SJ (2012) Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol 30(25):3058–3064.  https://doi.org/10.1200/jco.2012.41.9564 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lipscomb J, Gillespie TW, Goodman M, Richardson LC, Pollack LA, Ryerson AB, Ward KC (2012) Black-white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. Breast Cancer Res Treat 133(1):285–296.  https://doi.org/10.1007/s10549-011-1916-1 CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Silva A, Rauscher GH, Hoskins K, Rao R, Ferrans CE (2013) Assessing racial/ethnic disparities in chemotherapy treatment among breast cancer patients in context of changing treatment guidelines. Breast Cancer Res Treat 142(3):667–672.  https://doi.org/10.1007/s10549-013-2759-8 CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Wu XC, Lund MJ, Kimmick GG, Richardson LC, Sabatino SA, Chen VW, Fleming ST, Morris CR, Huang B, Trentham-Dietz A, Lipscomb J (2012) Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 30(2):142–150.  https://doi.org/10.1200/jco.2011.36.8399 CrossRefPubMedGoogle Scholar
  24. 24.
    Banerjee MGJ, Yee C, Hryniuk W, Schwartz K (2007) Disentangling the effects of race on breast cancer treatment. Cancer 110(10):2169–2177CrossRefPubMedGoogle Scholar
  25. 25.
    Bickell NAWJ., Oluwole S, Schrag D, Godfrey H, Hiotis K, Mendez J, Guth AA (2006) Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol 24(9):1357–1362CrossRefPubMedGoogle Scholar
  26. 26.
    Freedman RAHY., Winer EP, Keating NL (2009) Trends in racial and age disparities in definitive local therapy of early-stage breast cancer. J Clin Oncol 27(5):713–719CrossRefPubMedGoogle Scholar
  27. 27.
    Lund MJBO., Ward KC, Young JL, Gabram SS, Eley JW (2008) Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat 109(3):545–557CrossRefPubMedGoogle Scholar
  28. 28.
    Freedman RA, He Y, Winer EP, Keating NL (2013) Racial/ethnic differences in receipt of timely adjuvant therapy for older women with breast cancer: are delays influenced by the hospitals where patients obtain surgical care? Health Serv Res 48(5):1669–1683.  https://doi.org/10.1111/1475-6773.12063 PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    McLaughlin JM, Anderson RT, Ferketich AK, Seiber EE, Balkrishnan R, Paskett ED (2012) Effect on survival of longer intervals between confirmed diagnosis and treatment initiation among low-income women with breast cancer. J Clin Oncol 30(36):4493–4500.  https://doi.org/10.1200/jco.2012.39.7695 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Vandergrift JL, Niland JC, Theriault RL, Edge SB, Wong Y-N, Loftus LS, Breslin TM, Hudis CA, Javid SH, Rugo HS, Silver SM, Lepisto EM, Weeks JC (2013) Time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions. JNCI: J Natl Cancer Inst 105(2):104–112.  https://doi.org/10.1093/jnci/djs506 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Wheeler SB, Carpenter WR, Peppercorn J, Schenck AP, Weinberger M, Biddle AK (2012) Predictors of timing of adjuvant chemotherapy in older women with hormone receptor-negative, stages II–III breast cancer. Breast Cancer Res Treat 131(1):207–216.  https://doi.org/10.1007/s10549-011-1717-6 CrossRefPubMedGoogle Scholar
  32. 32.
    Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH (2008) Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 26(30):4891–4898.  https://doi.org/10.1200/jco.2007.14.1168 CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI, Jemal A (2016) Cancer statistics for African Americans, 2016: progress and opportunities in reducing racial disparities. CA: Cancer J Clin 66(4):290–308.  https://doi.org/10.3322/caac.21340 CrossRefGoogle Scholar
  34. 34.
    Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 101(14):984–992.  https://doi.org/10.1093/jnci/djp175 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    U.S. Bureau of Census. Geographic areas reference manual. U.S. Bureau of Census, Suitland, 1994. https://www.census.gov/geo/reference/garm.html. Accessed 18 July 2017

Copyright information

© This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2018

Authors and Affiliations

  1. 1.NCI/DCCPS/HDRP/HARBBethesdaUSA
  2. 2.Information Management ServicesCalvertonUSA
  3. 3.NCI/HDRPBethesdaUSA

Personalised recommendations